While HER3 has little to no tyrosine kinase activity on its own, its activation promotes tumors through dimerization or locking into place with HER2, which is believed to intensify its cancer ...

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Schematic illustration of ErbB receptor structures and dimerization patterns ... powerful approach to overcome resistance. By combining HER3-targeting antibodies with cytotoxic payloads, ADCs ...

HER3 functions through its interaction with other ErbB receptors, particularly HER2, forming potent signaling pairs that drive cell survival, proliferation, and metastasis. These dimerized ...

Building upon the EpiClick platform, Tharimmune is also developing a new generation of multispecific antibodies targeting HER2 and HER3, two validated drivers of cancer growth and metastases.

Patients with high-risk, hormone receptor (HR)-positive, HER2-negative breast cancer treated with presurgical patritumab deruxtecan (HER3-DXd) with or without Femara (letrozole) experienced similar ...

Building upon the EpiClick platform, Tharimmune is also developing a new generation of multispecific antibodies targeting HER2 and HER3, two validated drivers of cancer growth and metastases.